Solid Biosciences (SLDB) Non Operating Investment Income (2025 - 2026)
Quarterly results put Non Operating Investment Income at -$1.6 million for Q1 2026, changed 0.0% from a year ago — trailing twelve months through Mar 2026 was -$6.0 million (changed N/A YoY), and the annual figure for FY2025 was -$6.0 million, down 27.37%.
Solid Biosciences has reported Non Operating Investment Income over the past 2 years, most recently at -$1.6 million for Q1 2026.
- Non Operating Investment Income reached -$1.6 million in Q1 2026 per SLDB's latest filing, up from -$2.6 million in the prior quarter.
- Across five years, Non Operating Investment Income topped out at -$850000.0 in Q3 2025 and bottomed at -$2.6 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 235,807.00 |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 230,000.00 |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | - |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | - |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | - |
| 10 | Solid Biosciences | 713.77 Mn | 333.09 Mn | - | -1.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.65 Mn |
| Mar 31, 2026 | -1.65 Mn |
| Dec 31, 2025 | -2.65 Mn |
| Dec 31, 2025 | -2.65 Mn |
| Sep 30, 2025 | -850,000.00 |
| Sep 30, 2025 | -850,000.00 |
| Jun 30, 2025 | -900,000.00 |
| Jun 30, 2025 | -900,000.00 |
| Mar 31, 2025 | -1.65 Mn |
| Mar 31, 2025 | -1.65 Mn |